EnhanX Biotherapeutics

EnhanX Biotherapeutics is a pre-clinical stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) to treat cancer. The company utilizes a proprietary technology platform designed to optimize conjugation chemistry and incorporate novel payloads, aiming to significantly improve the therapeutic index of targeted oncology treatments. By addressing common limitations of first- and second-generation ADCs, such as systemic toxicity and limited efficacy in solid tumors, EnhanX seeks to provide more durable responses for patients. Founded by industry veterans with extensive experience in the ADC field, the company is headquartered in the San Francisco Bay Area and backed by leading life science venture capital firms.